0.7893
2.14%
-0.0181
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8074
Offen:
$0.8043
24-Stunden-Volumen:
2.81M
Relative Volume:
0.90
Marktkapitalisierung:
$280.26M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.1607
EPS:
-0.68
Netto-Cashflow:
$-162.37M
1W Leistung:
-25.46%
1M Leistung:
-59.48%
6M Leistung:
-52.69%
1J Leistung:
-26.84%
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
LXRX | 0.7901 | 280.26M | 1.21M | -177.12M | -162.37M | -0.68 |
VRTX | 449.64 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-03-07 | Eingeleitet | Jefferies | Hold |
2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
2019-07-29 | Herabstufung | Stifel | Buy → Hold |
2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
2018-07-31 | Bestätigt | Stifel | Buy |
2018-02-23 | Herabstufung | Needham | Buy → Hold |
2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
2017-03-01 | Bestätigt | Wedbush | Outperform |
2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
2016-08-05 | Bestätigt | Wedbush | Outperform |
2016-08-02 | Eingeleitet | Citigroup | Buy |
2016-03-02 | Bestätigt | Wedbush | Outperform |
2015-11-09 | Bestätigt | Wedbush | Outperform |
2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Lexicon: Q3 Earnings Snapshot - The Washington Post
FMR LLC's Strategic Acquisition of Lexicon Pharmaceuticals Shares - GuruFocus.com
LXRXLexicon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings: EPS of -$0. - GuruFocus.com
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Previ - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | LXRX Stock News - StockTitan
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga
HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times
Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - MSN
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter
Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha
Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch
Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com
FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive
Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline News & Insights
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista — Update - Morningstar
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):